Dosani Talib, Mailankody Sham, Korde Neha, Manasanch Elisabet, Bhutani Manisha, Tageja Nishant, Roschewski Mark, Kwok Mary, Kazandjian Dickran, Costello Rene, Burton Debra, Zhang Yong, Liewehr David, Steinberg Seth M, Maric Irina, Landgren Ola
a Department of Medicine , University Hospitals Case Medical Center , Cleveland , OH, USA.
b Myeloma Service, Department of Medicine , Memorial Sloan-Kettering Cancer Center , New York , NY, USA.
Leuk Lymphoma. 2018 May;59(5):1127-1132. doi: 10.1080/10428194.2017.1361026. Epub 2017 Aug 9.
Host-related immunodeficiency is known to play a role in the development of multiple myeloma (MM) from its precursor conditions (monoclonal gammopathy of undetermined significance, MGUS, smoldering multiple myeloma, SMM). In order to understand the underlying immune changes in this process, we characterized immune patterns from MGUS to SMM to MM. We further sought to identify potential novel immune biomarkers that may predict progression of SMM to MM. We characterized patterns of circulating lymphocytes in 181 patients using multiparametric flow cytometry. We found decreased B- (p = .0003), increased T- (p = .037) and unaltered NK cell proportions from MGUS to SMM to MM. To gain insights into functional variability, we further characterized immunophenotypic lymphocyte subsets, which uncovered differences in CD57 subsets. Specifically, we found that SMM patients who eventually progressed to MM showed decreased proportions of CD57-CD56 + (p = .0061) and CD57-CD16 + (p = .035) lymphocyte subsets. We thus report novel data characterizing the nature of host-related immunodeficiency in the development of MM. We show sequential changes in lymphocyte subsets from MGUS to SMM to MM. We further suggest that CD57 subsets may serve as potential markers of progression from SMM to MM. Our findings support the study of lymphocyte subsets in the search for immune biomarkers. Such markers could provide clinical guidance in managing myeloma precursor disease.
已知宿主相关免疫缺陷在多发性骨髓瘤(MM)从其前驱状态(意义未明的单克隆丙种球蛋白病,MGUS;冒烟型多发性骨髓瘤,SMM)发展过程中起作用。为了解这一过程中潜在的免疫变化,我们对从MGUS到SMM再到MM的免疫模式进行了特征描述。我们进一步试图识别可能预测SMM进展为MM的潜在新型免疫生物标志物。我们使用多参数流式细胞术对181例患者的循环淋巴细胞模式进行了特征描述。我们发现从MGUS到SMM再到MM,B细胞比例下降(p = 0.0003),T细胞比例增加(p = 0.037),NK细胞比例无变化。为深入了解功能变异性,我们进一步对免疫表型淋巴细胞亚群进行了特征描述,发现了CD57亚群的差异。具体而言,我们发现最终进展为MM的SMM患者中,CD57-CD56 + (p = 0.0061)和CD57-CD16 + (p = 0.035)淋巴细胞亚群的比例下降。因此,我们报告了关于MM发生发展过程中宿主相关免疫缺陷性质的新数据。我们展示了从MGUS到SMM再到MM淋巴细胞亚群的连续变化。我们进一步表明,CD57亚群可能作为SMM进展为MM的潜在标志物。我们的发现支持在寻找免疫生物标志物过程中对淋巴细胞亚群进行研究。此类标志物可为骨髓瘤前驱疾病的管理提供临床指导。